MDGL
Price
$432.94
Change
+$1.72 (+0.40%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
9.65B
54 days until earnings call
RNAC
Price
$10.62
Change
+$0.62 (+6.20%)
Updated
Sep 5, 04:58 PM (EDT)
Capitalization
276.66M
Interact to see
Advertisement

MDGL vs RNAC

Header iconMDGL vs RNAC Comparison
Open Charts MDGL vs RNACBanner chart's image
Madrigal Pharmaceuticals
Price$432.94
Change+$1.72 (+0.40%)
Volume$4.68K
Capitalization9.65B
Cartesian Therapeutics
Price$10.62
Change+$0.62 (+6.20%)
Volume$100
Capitalization276.66M
MDGL vs RNAC Comparison Chart in %
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. RNAC commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Buy and RNAC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (MDGL: $432.89 vs. RNAC: $10.64)
Brand notoriety: MDGL and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 70% vs. RNAC: 42%
Market capitalization -- MDGL: $9.65B vs. RNAC: $276.66M
MDGL [@Biotechnology] is valued at $9.65B. RNAC’s [@Biotechnology] market capitalization is $276.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileRNAC’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • RNAC’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 6 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).

  • MDGL’s TA Score: 6 bullish, 3 bearish.
  • RNAC’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than RNAC.

Price Growth

MDGL (@Biotechnology) experienced а -1.13% price change this week, while RNAC (@Biotechnology) price change was +5.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($9.65B) has a higher market cap than RNAC($277M). MDGL YTD gains are higher at: 40.289 vs. RNAC (-40.592). RNAC has higher annual earnings (EBITDA): -118.73M vs. MDGL (-266.74M). MDGL has more cash in the bank: 797M vs. RNAC (160M). RNAC has less debt than MDGL: RNAC (13.3M) vs MDGL (124M). MDGL has higher revenues than RNAC: MDGL (516M) vs RNAC (1.03M).
MDGLRNACMDGL / RNAC
Capitalization9.65B277M3,483%
EBITDA-266.74M-118.73M225%
Gain YTD40.289-40.592-99%
P/E RatioN/A1.98-
Revenue516M1.03M50,292%
Total Cash797M160M498%
Total Debt124M13.3M932%
FUNDAMENTALS RATINGS
MDGL vs RNAC: Fundamental Ratings
MDGL
RNAC
OUTLOOK RATING
1..100
2252
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
27100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3765
P/E GROWTH RATING
1..100
10040
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (67) in the Pharmaceuticals Other industry is somewhat better than the same rating for RNAC (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than RNAC’s over the last 12 months.

MDGL's Profit vs Risk Rating (27) in the Pharmaceuticals Other industry is significantly better than the same rating for RNAC (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than RNAC’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as RNAC (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to RNAC’s over the last 12 months.

MDGL's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as RNAC (65) in the Biotechnology industry. This means that MDGL’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that RNAC’s stock grew somewhat faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLRNAC
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 12 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IUASX31.94N/A
N/A
VY® Invesco Equity and Income S
LAMFX25.10N/A
N/A
Lord Abbett Dividend Growth F
FSEAX60.44N/A
N/A
Fidelity Emerging Asia
JHJAX24.47N/A
N/A
JHancock ESG Large Cap Core A
GAFFX86.20N/A
N/A
American Funds Growth Fund of Amer F3